<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154801</url>
  </required_header>
  <id_info>
    <org_study_id>P140709</org_study_id>
    <nct_id>NCT03154801</nct_id>
  </id_info>
  <brief_title>Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)</brief_title>
  <acronym>NEUROSEX</acronym>
  <official_title>Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to ensure that the implementation of a paramedical screening program and
      counseling in sexual health of patients with neurological pathologies (low-grade gliomas and
      Multiple Sclerosis) improves their sexual health.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of MSISQ15 sexual dysfunctional items at 3-months from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)</measure>
    <time_frame>Inclusion and 6-months</time_frame>
    <description>Change of MSISQ15 sexual dysfunctional items at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HAD scale (Hospital Anxiety and Depression)</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of HAD scale score at 3-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HAD scale (Hospital Anxiety and Depression)</measure>
    <time_frame>Inclusion and 6 months</time_frame>
    <description>Change of HAD scale score at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Rosenberg's Self-esteem Scale</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of Rosenberg's Self-esteem Scale score at 3-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Rosenberg's Self-esteem Scale</measure>
    <time_frame>Inclusion and 6 months</time_frame>
    <description>Change of Rosenberg's Self-esteem Scale score at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of life scale</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of Quality of life scale score at 3-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of life scale</measure>
    <time_frame>Inclusion and 6 months</time_frame>
    <description>Change of Quality of life scale score at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QLQ-C30/BM20 scale (Quality of Life Questionnaire - Core Questionnaire / Brain Module)</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of QLQC30/BM20 score at 3-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QLQ-C30/BM20 scale (Quality of Life Questionnaire - Core Questionnaire / Brain Module)</measure>
    <time_frame>Inclusion and 6 months</time_frame>
    <description>Assessment of QLQC30/BM20 score at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SEP59 scale (Sclérose En Plaques)</measure>
    <time_frame>Inclusion and 3 months</time_frame>
    <description>Change of SEP59 scale score at 3-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SEP59 scale (Sclérose En Plaques)</measure>
    <time_frame>Inclusion and 6 months</time_frame>
    <description>Change of SEP59 scale score at 6-months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Program satisfaction scale</measure>
    <time_frame>3 months</time_frame>
    <description>Program satisfaction scale scores at 3-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Program satisfaction scale</measure>
    <time_frame>6 months</time_frame>
    <description>Program satisfaction scale scores at 6-months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Low Grade Glioma of Brain</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Sexual Dysfunctions</condition>
  <arm_group>
    <arm_group_label>Paramedical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paramedical early detection of sexual dysfunction and sexual health counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paramedical care</intervention_name>
    <description>Paramedical early detection of sexual dysfunction and sexual health counseling</description>
    <arm_group_label>Paramedical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any major patient, followed in the GHPSCF (Groupe Hospitalier Pitié-Salpêtrière
             Charles Foix) neurology department 2 for a diagnosis of low grade glioma or anaplastic
             glioma with loss 1p / 19q sub-reserve histo-molecular confirmation after national
             reading (POLA) and presenting:

               -  An MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)
                  questionnaire with at least one of the items rated &quot;4&quot; or &quot;5&quot; and

               -  A HAD (Hospital Anxiety and Depression) questionnaire (depression component) with
                  a score ≤ 11

          2. Any major patient with MS(Multiple Sclerosis), followed in the GHPSCF Department of
             Neurology:

               -  With an EDSS (Expanded Disability Status Scale) greater than or equal to 1 and

               -  An MSISQ15 questionnaire with at least one of the items rated &quot;4&quot; or &quot;5&quot;.

               -  A HAD questionnaire (depression component) with a score ≤ 11

          3. Signature of informed consent

          4. Patient affiliated to a social security system

        Exclusion Criteria:

          1. Minor patients

          2. Pregnant women

          3. Patients who do not understand and / or speak French and / or are unable to sign
             consent

          4. Patients with neurological impairment

          5. Patients with chronic sexual disorders who have already received treatment.

          6. Patients with a HAD score (depression component) greater than 11

          7. Patients with MS who had a corticosteroid-treated outbreak in the last two months.

          8. Patients with low-grade glioma with clinical and / or radiological scalability during
             the last three months

          9. Any patient whose alteration of the general state would not allow to follow the
             program.

         10. Patients under legal protection

        For patient's partners:

        Inclusion criteria:

          1. Any patient partner, whose patient has wished to participate and who has accepted.

          2. Signing of informed consent

        Non-Inclusion Criteria:

          1. Minor partners

          2. Pregnant women

          3. Any person who does not understand and / or speak French and / or is unable to sign
             the consent

          4. Partners under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence LAIGLE-DONADEY, MD</last_name>
      <phone>+33(0)1 42 16 03 81</phone>
      <email>florence.laigle-donadey@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

